Showing results (61-70 of 2,459) with videos related to
Sort By:
Pageof 246
Journal of Virology|January 30, 2009
Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infectionsAndrea R Stacey, Philip J Norris, Li Qin, et al.Journal of the Pediatric Infectious Diseases Society|December 1, 2015
Implications of Age-Dependent Immune Responses to Enterovirus 71 Infection for Disease Pathogenesis and Vaccine DesignSoren Gantt, Lena Yao, Tobias R Kollmann, et al.Plos Computational Biology|December 7, 2007
Direct inference of SNP heterozygosity rates and resolution of LOH detectionXiaohong Li, Steven G Self, Patricia C Galipeau, et al.Vaccine|December 3, 2011
Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeysDavid R Kaufman, Fusheng Li, Ashley N Cruz, et al.The International Journal of Biostatistics|November 4, 2011
Commentary on "Principal stratification - a goal or a tool?" by Judea PearlPeter B Gilbert, Michael G Hudgens, Julian WolfsonBiometrics|March 2, 2005
Two-sample tests for comparing intra-individual genetic sequence diversity between populationsPeter B Gilbert, A J Rossini, Raj ShankarappaCurrent HIV Research|February 3, 2007
Identification of cross-neutralization determinants by GAP analysis: a mutational behavior approachFusheng Li, Peter B Gilbert, Steve G SelfCurrent Opinion in HIV and AIDS|May 31, 2013
Sieve analysis in HIV-1 vaccine efficacy trialsPaul T Edlefsen, Peter B Gilbert, Morgane RollandBiostatistics (Oxford, England)|August 21, 2007
The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacyPeter B Gilbert, Ian W McKeague, Yanqing SunStatistics in Medicine|April 3, 2016
Power/sample size calculations for assessing correlates of risk in clinical efficacy trialsPeter B Gilbert, Holly E Janes, Yunda HuangPageof 246